AC8 — Auscann group Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedMicro Cap
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -132.41% | ||
| Return on Equity | -78.72% | ||
| Operating Margin | -460.74% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.86 | 0.39 | 1.82 | 1.64 | 1.87 | n/a | n/a | 51.37% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AusCann Group Holdings Limited is an Australia-based company focused on the development and commercialization of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. It has launched tetrahydrocannabinol and cannabidiol (THC/CBD) powder-based hard-shell capsules, based on the Company’s Neuvis platform, for the treatment of pain and related indications. Its products include CPAT-01, DermaCann and MicroMax. CPAT-01 is a liquid, oral veterinary medicine containing standardized tetrahydrocannabinol (THC) and cannabinoids (CBD) whole plant extracts in a proprietary ratio to target pain and inflammation in dogs. DermaCann is a CBD-derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. The product is a liquid oral oil formulation containing CBD in a patented combination with other bioactive lipids designed to target inflammation and immune modulation pathways.
Directors
- Tod McGrouther CHM (57)
- Layton Mills CEO
- Charles Altshuler CFO
- Maria Alexakis OTH
- Susan Hunter SEC
- Krista Bates NED
- Robert Clifford NED
- Christopher Mews NED
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- February 26th, 1986
- Public Since
- May 3rd, 1989
- No. of Shareholders
- 15,023
- No. of Employees
- 27
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 440,547,110
- Address
- Wangara, PERTH, 6947
- Web
- https://auscann.com.au/
- Phone
- +61 863050705
- Auditors
- PKF Perth
Upcoming Events for AC8
Auscann Group Holdings Ltd Annual Shareholders Meeting
Similar to AC8
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Anatara Lifesciences
Australian Stock Exchange - SEATS
Argent BioPharma
Australian Stock Exchange - SEATS
FAQ
What is the Auscann group share price?
As of Today at 19:26 UTC, shares in Auscann group are trading at AU$0.04. This share price information is delayed by 15 minutes.
How has the Auscann group share price performed this year?
Shares in Auscann group last closed at AU$0.04 and the price had moved by -57.45% over the past 365 days. In terms of relative price strength the Auscann group share price has underperformed the ASX All Ordinaries Index by -61.82% over the past year.
What are the analyst and broker recommendations for Auscann group?
There is no consensus recommendation for this security.
Find out moreWhat is the Auscann group dividend yield?
Auscann group does not currently pay a dividend.
Does Auscann group pay a dividend?
Auscann group does not currently pay a dividend.
When does Auscann group next pay dividends?
Auscann group does not currently pay a dividend.
How do I buy Auscann group shares?
To buy shares in Auscann group you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Auscann group?
As of the previous close price of AU$0.04, shares in Auscann group had a market capitalisation of .
Where are Auscann group shares listed?
Here are the trading details for Auscann group:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AC8
What kind of share is Auscann group?
Based on an overall assessment of its quality, value and momentum Auscann group is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Auscann group share price forecast for 2024?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Auscann group share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Auscann group. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -41.9%.
As of the last closing price of AU$0.04, shares in Auscann group were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Auscann group PE Ratio?
The Auscann group PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.04.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Auscann group?
Auscann group's management team is headed by:
- Tod McGrouther - CHM
- Layton Mills - CEO
- Charles Altshuler - CFO
- Maria Alexakis - OTH
- Susan Hunter - SEC
- Krista Bates - NED
- Robert Clifford - NED
- Christopher Mews - NED